A Starpharma snapshot:
22 years as a listed entity on the ASX.
Approximately $220 million of accumulated losses according to the financial reports.
Jackie Fairley now into her 17th year as CEO.
After 22 years, Starpharma still does not have one single drug under development, partnered or in-house that is in a blind or randomised clinical trial.
All trials are non-randomised and open-label. Think about that….
Time for a shake up IMHO.
Starpharma after 22 years
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |